| Literature DB >> 17376240 |
Jeana T DaRe1, Rajeev K Mehlotra, Pascal Michon, Ivo Mueller, John Reeder, Yagya D Sharma, Mark Stoneking, Peter A Zimmerman.
Abstract
BACKGROUND: Polymorphism in the pfcrt gene underlies Plasmodium falciparum chloroquine resistance (CQR), as sensitive strains consistently carry lysine (K), while CQR strains carry threonine (T) at the codon 76. Previous studies have shown that microsatellite (MS) haplotype variation can be used to study the evolution of CQR polymorphism and to characterize intra- and inter-population dispersal of CQR in Papua New Guinea (PNG).Entities:
Mesh:
Substances:
Year: 2007 PMID: 17376240 PMCID: PMC1838424 DOI: 10.1186/1475-2875-6-34
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Prevalence of pfcrt alleles (codons 72–76) in malaria-endemic regions of PNG
| n = 7 | Liksulb | Dreikikirc | Woserad | Woserae | |
| CVMNK | 0.143 | 0.045 | 0.484 | 0.241 | 0.097 |
| SVMNT | 0.857 | 0.955 | 0.516 | 0.572 | 0.791 |
| CVIET | 0 | 0 | 0 | 0.006f | 0.013 |
| CVMNK + SVMNT | 0 | 0 | 0 | 0.181 | 0.086 |
| CVMNK + CVIET | 0 | 0 | 0 | 0 | 0.002 |
| SVMNT + CVIET | 0 | 0 | 0 | 0 | 0.012 |
a, b, c Samples with mixed infections were not included.
a Samples were collected from the Eastern Highlands (n = 1), East Sepik (n = 3), Manus (n = 1), Milne Bay (n = 1), and Morobe (n = 1) provinces of PNG between 1982 and 1984 and were previously reported [8].
b, c Samples were collected in 1996 and were previously reported [7].
d Samples were collected in 1998 and 2002. The 1998 samples were previously reported [7].
e Samples were collected between 2001 and 2003 in local health centers.
f Allele found only in samples taken from the 2002 group.
Figure 1Agarose gel showing PCR products with size variability. PCR products for pfcrt codons 152–163 genotyping assay showing size variation between samples. Lanes 2, 4, 6, 8, and 10 contain PNG samples collected from the Wosera in 2002. The other lanes contain laboratory-adapted strains, lane 1-Dd2, 3-7G8, 5-PNG1917, 7-PNG1905, and 9-K1.
Heterozygosity (± standard deviation) of MS loci associated with pfcrt-SVMNTa allele in post-1995 samples.
| B5M77 | -18 kb | 0 | .342 ± .140 | .060 ± .026 |
| 2E10 | -5 kb | 0 | .154 ± .126 | .049 ± .024 |
| msint1d | 0 kb | - | - | .051 ± .034e |
| msint2 | 0 kb | .091 ± .081 | .380 ± .134 | .196 ± .039 |
| msint3 | 0 kb | 0 | .314 ± .138 | .056 ± .024 |
| 9B12 | +2 kb | .181 ± .104 | .275 ± .145 | .045 ± .030 |
| +7 kb | .450 ± .128 | .275 ± .148 | .220 ± .042 | |
| 2H4 | +19 kb | .710 ± .060 | .781 ± .102 | .746 ± .020 |
| PfPK2 | --- | .617 ± .063 | .769 ± .083 | .744 ± .019 |
a 21/22 infections in Liksul, 16/31 in Dreikikir, and 169/761 in Wosera carried the pfcrt-SVMNT allele.
b Wosera group contains both clinical and community samples.
c PCR for Liksul samples was 100% for all loci except cg2 (.905). Frequency of amplification for each locus for Dreikikir and Wosera, respectively, were B5M77, 0.875, 0.970; 2E10, 0.813, 0.941; 9B12, 0.813, 0.941; cg2, 0.813, 0.976; 2H4, 0.875, 0.935; and PfPK2, 0.813, 0.935.
d MS also known as B5M47.
e Value based only on 78 of the 82 clinical samples and no community samples.
Figure 2Heterozygosity of . Graphic representation of heterozygosity values for pfcrt intronic and flanking MS in pfcrt-CVMNK and SVMNT samples from all study sites. Data for msint1 is available only from pfcrt-SVMNT clinical samples collected from the Wosera.
Fst values to measure genetic diversity between groups of pfcrt-SVMNT samples from post-1995 collections
| B5M77 | 0.12* | -0.01 | 0.17* |
| 2E10 | 0.04 | -0.02 | 0.04 |
| msint2 | 0.03 | -0.01 | 0.01 |
| msint3 | 0.07 | -0.01 | 0.12 |
| 9B12 | -0.04 | 0.04 | 0.10 |
| 0.00 | 0.04 | -0.01 | |
| 2H4 | 0.07* | 0.10* | 0.08* |
| PfPK2 | 0.07* | 0.01 | 0.03 |
* indicates that the value is significantly different from zero (p < 0.05).
Intronic haplotype frequencies for pfcrt-SVMNT and CVIET samplesa
| Liksul | Dreikikir | Wosera | Wosera | |||
| SVMNT | SVMNT | SVMNT | SVMNT | SVMNT | CVIET | |
| 3_8 | 0.667 | 0.955 | 0 | |||
| 7_8 | 0 | 0.045 | 0 | |||
| 8_3 | 0.167 | 0 | 0 | 0 | ||
| 3_2 | 0.167 | 0 | 0 | 0 | 0 | 0 |
| 7_4 | 0 | 0 | 0 | 0 | ||
| 3_3 | 0 | 0 | 0.048 | 0 | 0 | 0 |
| 3_6 | 0 | 0 | 0.048 | 0 | ||
| 6_6 | 0 | 0 | 0 | 0 | 0 | |
| 10_8 | 0 | 0 | 0.048 | 0 | 0 | 0 |
| 8_8 | 0 | 0 | 0 | 0 | ||
| 9_8 | 0 | 0 | 0 | 0.011 | 0 | 0 |
| 2_8 | 0 | 0 | 0 | 0.011 | 0 | 0.500 |
| 4_8 | 0 | 0 | 0 | 0 | 0 | |
| 1_8 | 0 | 0 | 0 | 0 | 0 | 0.333 |
| 8_7 | 0 | 0 | 0 | 0 | 0 | 0.167 |
a Total number of samples 215: early 1980's (6), Liksul (21), Dreikikir (16), Wosera community samples (85), Wosera clinical samples (81 SVMNT, 6 CVIET).
b "n" indicates the number of haplotype infections present, which may or may not be equal to the total number of samples due to mixed haplotypes in some samples. Overall, 225 haplotypes were found in 215 samples.
c Frequencies in bold indicate that the haplotype was also observed in the CQS samples from that region.